Literature DB >> 18339440

A report on the diagnosis of intermediate hyperglycemia in Korea: A pooled analysis of four community-based cohort studies.

Jee-Young Oh1, Soo Lim, Dae Jung Kim, Nan Hee Kim, Dong Jun Kim, Sung Dae Moon, Hak Chul Jang, Young Min Cho, Kee-Ho Song, Chul Woo Ahn, Yeon-Ah Sung, Joong-Yeol Park, Chol Shin, Hong Kyu Lee, Kyong Soo Park.   

Abstract

Many studies show poor agreement between fasting plasma glucose (FPG)-based and 2-h postchallenge glucose (2-h PG)-based criteria to assess glucose metabolism. We examined the rate of agreement between FPG- and 2-h PG-based criteria in the diagnosis of intermediate hyperglycemia in four representative cohort studies in South Korea and compared the clinical characteristics and biochemical parameters in subjects with impaired fasting glucose (IFG) according to their FPG values. Of 6234 subjects from four population-based studies performed from 1993 to 2000, 4610 individuals with data from a 75g oral glucose tolerance test (OGTT) and no previous history of diabetes were selected. We examined the concordance rate between the FPG and 2-h PG-based criteria. We also investigated the differences in the clinical characteristics and biochemical parameters between individuals with IFG according to their FPG values. The fasting and 2-h PG criteria had large discordance rates in the diagnosis of diabetes and impaired glucose tolerance (IGT) in Korean adults. When individuals with IFG were classified into stage 1 [5.6-6.1mmol/L (100-109mg/dL)] and stage 2 [6.1-7.0mmol/L (110-125mg/dL)] IFG, individuals with stage 2 IFG are more obese and had higher blood pressure and total cholesterol and triglycerides concentrations compared with those with stage 1 IFG. In addition, more individuals with stage 2 IFG were with diabetes as determined by a 2-h PG>or=11.1mmol/L (14.1% vs. 1.9%) (P<0.05). Considering the poorer metabolic profile and higher percentage of people with diabetes by OGTT, these data indicate that, in the Korean population, individuals with stage 2 IFG should be treated differently from those with stage 1 IFG. To detect more cases of diabetes, the OGTT is recommended for all individuals with stage 2 IFG and cases with stage 1 IFG with some additional risk factors for diabetes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18339440     DOI: 10.1016/j.diabres.2008.01.022

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  15 in total

1.  A simple screening score for diabetes for the Korean population: development, validation, and comparison with other scores.

Authors:  Yong-Ho Lee; Heejung Bang; Hyeon Chang Kim; Hee Man Kim; Seok Won Park; Dae Jung Kim
Journal:  Diabetes Care       Date:  2012-06-11       Impact factor: 19.112

2.  Prevalence of Diabetes Mellitus and Prediabetes in Dalseong-gun, Daegu City, Korea.

Authors:  Jung-Eun Lee; Sung-Chang Jung; Gui-Hwa Jung; Sung-Woo Ha; Bo-Wan Kim; Shung-Chull Chae; Wee-Hyun Park; Ji-Sun Lim; Jin-Hoon Yang; Sin Kam; Byung-Yeol Chun; Jong-Yeon Kim; Jung-Jeung Lee; Kyeong-Soo Lee; Moon-Young Ahn; Young-Ae Kim; Jung-Guk Kim
Journal:  Diabetes Metab J       Date:  2011-06-30       Impact factor: 5.376

3.  2011 clinical practice guidelines for type 2 diabetes in Korea.

Authors:  Seung-Hyun Ko; Sung-Rea Kim; Dong-Joon Kim; Seung-Joon Oh; Hye-Jin Lee; Kang-Hee Shim; Mi-Hye Woo; Jun-Young Kim; Nan-Hee Kim; Jae-Taik Kim; Chong Hwa Kim; Hae Jin Kim; In-Kyung Jeong; Eun-Kyung Hong; Jae-Hyoung Cho; Ji-Oh Mok; Kun-Ho Yoon
Journal:  Diabetes Metab J       Date:  2011-10-31       Impact factor: 5.376

4.  Is an Oral Glucose Tolerance Test Still Valid for Diagnosing Diabetes Mellitus?

Authors:  Dong Lim Kim; Sun Doo Kim; Suk Kyeong Kim; Sooyoun Park; Kee Ho Song
Journal:  Diabetes Metab J       Date:  2016-04       Impact factor: 5.376

5.  Changing Clinical Characteristics according to Insulin Resistance and Insulin Secretion in Newly Diagnosed Type 2 Diabetic Patients in Korea.

Authors:  Jang Won Son; Cheol-Young Park; Sungrae Kim; Han-Kyu Lee; Yil-Seob Lee
Journal:  Diabetes Metab J       Date:  2015-10-22       Impact factor: 5.376

6.  Body mass index and waist circumference according to glucose tolerance status in Korea: the 2005 Korean Health and Nutrition Examination Survey.

Authors:  Hye Mi Kang; Dong-Jun Kim
Journal:  J Korean Med Sci       Date:  2012-04-25       Impact factor: 2.153

7.  Low pulmonary function in individuals with impaired fasting glucose: the 2007-2009 Korea national health and nutrition examination survey.

Authors:  Yun Jeong Lee; Na Kyung Kim; Ju Yean Yang; Jung Hyun Noh; Sung-Soon Lee; Kyung Soo Ko; Byoung Doo Rhee; Dong-Jun Kim
Journal:  PLoS One       Date:  2013-09-27       Impact factor: 3.240

8.  Plasma glucose regulation and mortality in Korea: a pooled analysis of three community-based cohort studies.

Authors:  Nan Hee Kim; Dong-Jun Kim; Seok Won Park; Jee-Young Oh; Joong-Yeol Park; Chol Shin; Hong Kyu Lee; Yongsoo Park
Journal:  Diabetes Metab J       Date:  2014-02-19       Impact factor: 5.376

9.  Prevalence of Diabetes and Prediabetes according to Fasting Plasma Glucose and HbA1c.

Authors:  Ja Young Jeon; Seung-Hyun Ko; Hyuk-Sang Kwon; Nan Hee Kim; Jae Hyeon Kim; Chul Sik Kim; Kee-Ho Song; Jong Chul Won; Soo Lim; Sung Hee Choi; Myoung-Jin Jang; Yuna Kim; Kyungwon Oh; Dae Jung Kim; Bong-Yun Cha
Journal:  Diabetes Metab J       Date:  2013-10-17       Impact factor: 5.376

10.  2021 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association.

Authors:  Kyu Yeon Hur; Min Kyong Moon; Jong Suk Park; Soo-Kyung Kim; Seung-Hwan Lee; Jae-Seung Yun; Jong Ha Baek; Junghyun Noh; Byung-Wan Lee; Tae Jung Oh; Suk Chon; Ye Seul Yang; Jang Won Son; Jong Han Choi; Kee Ho Song; Nam Hoon Kim; Sang Yong Kim; Jin Wha Kim; Sang Youl Rhee; You-Bin Lee; Sang-Man Jin; Jae Hyeon Kim; Chong Hwa Kim; Dae Jung Kim; SungWan Chun; Eun-Jung Rhee; Hyun Min Kim; Hyun Jung Kim; Donghyun Jee; Jae Hyun Kim; Won Seok Choi; Eun-Young Lee; Kun-Ho Yoon; Seung-Hyun Ko
Journal:  Diabetes Metab J       Date:  2021-07-30       Impact factor: 5.376

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.